[Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia].
The author presents the results of a cross-over blind trial of induracin, prolonged nicotinic acid. The study covered 31 dyslipoproteinemic patients and lasted 6 months. The treatment gave rise to a significant fall in the total cholesterol, LDL cholesterol, triglycerides (by 11%, 17% and 19% respectively), HDL cholesterol levels went up by 14%, lipid transport proteins proportions changed for the better (AI apoprotein increased by 15% against lowering of apoprotein B by 29%). The drug was well tolerated.